Welcome to Psychiatryai.com: Latest Evidence - RAISR4D

Estimated reading time for CME/CPD: 2 mins

The prevalence of metabolic syndrome in patients with non-alcoholic fatty liver disease: Systematic review and meta-analysis of observational studies

AI Summary
  • Pooled prevalence of metabolic syndrome among non-alcoholic fatty liver disease patients was 38% (95% CI 29-48).
  • Prevalence varied by metabolic syndrome diagnostic criteria: NCEP/ATP III 40% (95% CI 29-52); IDF 32% (95% CI 29-36).
  • Regional pooled prevalence ranged 33% to 47% across WHO regions; effective prevention strategies are recommended to mitigate morbidity and mortality.
Summarise with AI (MRCPsych/FRANZCP)

Sage Open Chronic Dis. 2026 Jul 28;17:27558428261471362. doi: 10.1177/27558428261471362. eCollection 2026 Jan-Dec.

ABSTRACT

BACKGROUND: The association between metabolic syndrome (MetS) and non-alcoholic fatty liver disease is well recognized. However, the prevalence of MetS among patients with non-alcoholic fatty liver disease in different studies varied considerably. Moreover, an up-to-date and pooled estimate of MetS in that group is limited. Therefore, this systematic review and meta-analysis aimed to estimate the pooled prevalence of metabolic syndrome among patients with non-alcoholic fatty liver disease.

OBJECTIVE: To estimate the pooled prevalence of metabolic syndrome among patients with non-alcoholic fatty liver disease.

DESIGN: Systematic review and meta-analysis.

DATA SOURCE AND METHODS: This systematic review and meta-analysis included original articles published in English. Multiple databases, including PubMed, Google Scholar, Web of Science, and Cochrane Library, were searched to identify all relevant publications. A random-effects model was used to obtain the pooled estimate. Statistical heterogeneity was assessed using the Cochrane Q test and the I 2 statistic. Funnel plot and Egger’s regression statistical test were utilized to measure publication bias. This systematic review and meta-analysis were based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Statement.

RESULT: Initially, a total of 1432 articles were retrieved using electronic databases. After duplication removal, title/abstract screening, and eligibility assessment, 9 studies (12 prevalence estimates) were selected for review. The random effect model indicated that the pooled prevalence of MetS among non-alcoholic fatty liver disease patients was 38% (95% CI: 29-48). Subgroup analysis by MetS diagnostic criteria indicated that the pooled prevalence was 40% (95% CI: 29-52) in NCEP/ATP III criteria-based studies and 32% (95% CI: 29-36) in International Diabetic Federation (IDF) criteria-based studies, respectively. Additionally, subgroup analysis by WHO region also showed that the pooled prevalence ranged from 33% to 47% in the Southeast Asia region and the Eastern Mediterranean region. The visual funnel plot did not suggest asymmetry, and the Eggers test did not indicate publication bias.

CONCLUSION: The findings of this review indicated that a substantial number of people are affected by MetS among patients who have non-alcoholic fatty liver disease. An effective prevention strategy to mitigate morbidity and mortality associated with MetS is recommended.

PMID:43034456 | PMC:PMC13768690 | DOI:10.1177/27558428261471362

Document this CPD

Share Evidence Blueprint

QR Code

Save to Google Notes

Search Google Scholar

⭐ My Revision List

close chatgpt icon
ChatGPT

Enter your request.

←
RAISR4D CME/CPD Evidence Nodes
Explore previous RAISR4D CME/CPD evidence nodes.
CME/CPD